Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
podoplanin antibody
- Development stage
- Unknown
- Lead developer
- Tohoku University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Podoplanin (PDPN), also known as Aggrus or T1-alpha, is a type I transmembrane sialoglycoprotein that is highly expressed on lymphatic endothelial cells and upregulated in various human cancers, including glioblastoma, malignant mesothelioma, and squamous cell carcinomas. Podoplanin antibodies are designed to bind to the extracellular domain of PDPN, particularly the platelet aggregation-stimulating (PLAG) domains. By blocking the interaction between PDPN and the C-type lectin-like receptor 2 (CLEC-2) on platelets, these antibodies can inhibit tumor cell-induced platelet aggregation and hematogenous metastasis. Beyond therapeutic applications, podoplanin antibodies are widely used as diagnostic tools in flow cytometry and immunohistochemistry to identify lymphatic vessel invasion and to distinguish specific malignancies, such as Acute Promyelocytic Leukemia (APL), from other forms of leukemia.
- Other names
- anti-podoplanin antibodyanti-PDPN antibodyPDPN antibodyanti-Aggrus antibody
02
Targets
PDPN (Podoplanin)
Beyond the preview
Go deeper on podoplanin antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on podoplanin antibody.